Latest Conference Articles

ICON-1 plus ranibizumab effectively reduced CNV size and led to complete drying of the retina for some patients with wet AMD.

Pravin Dugel, MD, talks about the study results for OPT-302 and the possibilities that further data could provide for DME, nAMD, and diabetic retinopathy.

Patients taking 440µg doses of the drug saw better results than those treated with 44µg doses

Intravitreal bevacizumab effectively lowered the risk of retinal detachment recurrence after primary pars plana vitrectomy.

Patients experienced prolonged time to treatment failure, meeting primary endpoints in VISUAL I and II trials.

Improvements in visual acuity were less pronounced in the "real-world" setting compared with randomized trials for diabetic macular edema.

Jeffrey Luttrull, MD, speaks about the reduced risk of choroidal neovascularization following use of the subthreshold diode micropulse laser (SDM) retinal protective therapy™ (RPT) for patients with Dry AMD.

Jeffrey Heier talks about RGX-314 gene therapy and the advantages of subretinal delivery.

Patients treated with C3F8 saw a superlative 84% release rate, according to study authors.

RGX-314 could help to alleviate the overall treatment burden for patients with wet age-related macular degeneration via a one-time subretinal injection.

The TOLEDO study noted it also increased “on” time without troublesome dyskinesia.

No evidence of adverse events or significant safety concerns has surfaced.

The development was presented by David Eidelberg, MD, at the 21st International Congress of Parkinson's Disease and Movement Disorders.

Scores on key scales improved 20%–28% after 1 year of jejunal levodopa/carbidopa.

Patient- and clinician-rated outcomes were keys in supporting labeling claims.

The method alleviates the 2 drugs' strained efficacy over time during Parkinson's progression.

Benefit was seen in 5 countries regardless of SGLT2 inhibitor used.

Human antibody may substantially reduce need for insulin in patients with T1D.

RT002 could treat moderate to severe isolated cervical dystonia with 2 or fewer annual shots.

Kausik Ray highlights the differences between the ODYSSEY DM-INSULIN trial differ from previous trials of PCSK9 inhibitors.

Samuel Frank, MD, director of the Huntington's Disease Society America Centers of Excellence at the Beth Israel Deaconness Medical Center, discusses hitting the moving target of Huntington's treatment, and his research on deutetrabenazine for the rare disease.

Results have major worldwide implications for type 2 diabetes treatment.

New-generation insulin found to have comparable cardiovascular safety to insulin glargine and significantly reduce episodes of severe hypoglycemia.

Investigational levodopa form CVT-301 improves "off" period motor function.

Two pivotal studies on sotagliflozin were presented at the ADA’s 77th Scientific Sessions.

Insulin glargine 100 Units/mL and lixisenatide 33 mcg/mL combined lowered A1C levels by 1.09% to 2.41% after 30 weeks.

Metformin may reduce the risk of heart disease in adults with T1D.

ODYSSEY DM-DYSLIPIDEMIA is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.

ODYSSEY DM-INSULIN is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.

Merck and Pfizer have announced that VERTIS MET and VERTIS SITA met primary endpoints.